DexCom, Inc.
Financials
Valuation Metrics
DexCom, Inc.'s Market Cap is $31.99B. At end of 2025 it was $25.67B. Ranked #441 of 3,118 in US market (top 14%), #130 of 1,474 on NASDAQ (top 9%), #31 of 203 in Health Care Equipment & Services (top 15%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $31.99B | US#441/3,118 Sec#31/203 |
| Revenue | $5.10B | US#889/3,118 Sec#51/203 |
| Net Income | $991M | US#544/3,118 Sec#32/203 |
| Total Assets | $6.24B | US#1,259/3,118 Sec#56/203 |
| Net Assets | $2.54B | US#1,056/3,118 Sec#55/203 |
| Employees | 11,000 | US#810/3,118 Sec#62/203 |
| Value | ||
| P/E | 32.28x | US#1,608/3,118 Sec#60/203 |
| P/B | 12.62x | US#2,674/3,118 Sec#175/203 |
| PEG | 0.86x | US#535/3,118 Sec#20/203 |
| P/S | 6.27x | US#2,458/3,118 Sec#159/203 |
| EV/EBITDA | 20.91x | US#1,910/3,118 Sec#88/203 |
| FCF Yield | 3.43% | US#1,487/3,118 Sec#75/203 |
| Profitability | ||
| ROE | 39.09% | US#193/3,118 Sec#10/203 |
| ROA | 15.88% | US#218/3,118 Sec#9/203 |
| Op. Margin | 23.98% | US#760/3,118 Sec#19/203 |
| Revenue Growth | 13.03% | US#880/3,118 Sec#61/203 |
| Earnings Growth | 37.51% | US#367/3,118 Sec#15/203 |
| Financial Health | ||
| Debt Ratio | 146.07% | US#1,471/3,118 Sec#133/203 |
| Total Debt | $1.39B | US#1,344/3,118 Sec#70/203 |
| FCF | $1.10B | US#462/3,118 Sec#31/203 |
| Cash | $961M | US#627/3,118 Sec#33/203 |
| Current Ratio | 1.74x | US#1,426/3,118 Sec#125/203 |
| Net Debt/EBITDA | 0.28x | US#667/3,118 Sec#48/203 |
| Performance | ||
| 1Y Return | 45.60% | US#1,114/3,118 Sec#95/203 |
| 1M Return | -0.69% | US#2,165/3,118 Sec#161/203 |
| From 52W High | -8.45% | US#876/3,118 Sec#74/203 |
| 1Y MDD | -22.61% | US#800/3,118 Sec#21/203 |
| Trading | ||
| Volume | 3,173,876 shares | US#271/3,118 Sec#10/203 |
| Trading Value | $267M | US#200/3,118 Sec#15/203 |
| Per Share | ||
| EPS | $2.63 | US#1,142/3,118 Sec#61/203 |
| BPS | $6.72 | US#2,092/3,118 Sec#126/203 |
Company Info
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.